MedAlliance gains CE Mark approval for coronary SELUTION SLR™ Sirolimus Drug Eluting Balloon

Mumbai (Maharashtra) [India] June 16 (ANI/PRNewswire): MedAlliance has announced the award of its second CE Mark: SELUTION SLR™ 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease.
This includes indications for both de-novo lesions as well as in-stent restenosis. The approval applies to a broad range of balloon sizes, from 1.5 x 10mm up to 5.0 x 40mm.
This award was supported by one-year results from the SELUTION SLR First-in-Human study, involving 56 patients enrolled across six Indian centres, nearly half (46.6 per cent) of whom had diabetes. 87.6 per cent of patients had de-novo lesions and 12.4 per cent had in-stent restenosis (ISR) lesions.
The primary endpoint of the study, freedom from device and procedure-related mortality through 30 days, was achieved in 100 per cent of patients.
There was no MACE (Major Adverse Cardiovascular Events) reported up to 30 days and only one case occurring up to one year. SELUTION SLR demonstrated similar efficacy and safety to a drug-eluting stent (DES), with only a single patient requiring a TLR (Target Lesion Revascularization). This single TLR case accounted for the low overall MACE rate of 2 per cent at 12 months.
Co-Principal Investigators Dr Shirish (MS) Hiremath (Director of Cath Lab and Consultant Cardiologist, Ruby Hall Clinic) and Dr Praveen Chandra (Chairman - Department of Interventional Cardiology, Medanta- The Medicity) concluded that the data in this study support the safety, efficacy and optimal performance of SELUTION SLR in coronary applications.
"We are excited about the new technology in Limus DEB SELUTION SLR," said Dr (Shirish) MS Hiremath. "DES has been the mainstay of treating CAD for many years. But the small vessel, long lesion, bifurcation and side branches, instent re-stenosis have been particularly challenging. With the LIMUS DEB (SELUTION) we can now offer alternative treatment modality and also 'Leave Nothing Behind' to allow complete healing," he added.
"I am extremely pleased with the CE Mark approval of this innovative technology," added Dr Chandra. "Small vessels and ISR are challenges for existing DES and DEB technologies, but this exciting new tool of a limus-eluting balloon can truly address the coronary conundrum of leaving nothing behind in the coronary artery, for complete healing," said Dr Chandra.
"We are very excited to have been awarded our second CE Mark, which is testament to the documented efficacy and safety of our novel sustained-release limus-eluting balloon in the treatment of coronary applications," concluded Jeffrey B. Jump, MedAlliance Chairman and CEO.
"SELUTION SLR is designed to deliver the same safety and performance as best-in-class DES technology with the added benefit of leaving nothing behind," he added.
In February 2020 MedAlliance received CE Mark approval for SELUTION SLR for the treatment of peripheral artery disease. The company recently announced the completion of its below-the-knee (BTK) First-in-Human study in Singapore.
The SAVE Study in Arterial Venus Fistula (AVF) enrolled its first patient in April. The STEP Pedal Arch study is to commence enrollment this quarter. A 500 patient post marketing clinical study will follow as well as the US IDE ISR study which will begin enrolment later this quarter.
MedAlliance is the first DEB company in the world to receive the US Food and Drug Administration (FDA) Breakthrough Device Designation Status for a coronary DEB.
SELUTION SLR has now achieved this status for a range of indications: the treatment of AV-Fistula; coronary in-stent restenosis and peripheral below-the-knee lesions.
SELUTION SLR's technology involves unique MicroReservoirs made from biodegradable polymer intermixed with the anti-restenotic drug sirolimus.
These MicroReservoirs provide controlled and sustained release of the drug. Extended release of sirolimus from stents has been proven highly efficacious in both coronary and peripheral vasculatures.
MedAlliance's proprietary CAT™ (Cell Adherent Technology) enables the MicroReservoirs to be coated onto balloons and adhered to the vessel lumen when delivered via an angioplasty balloon.
This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article (ANI/PRNewswire)